Recent updates in therapeutic approach using tolvaptan for autosomal dominant polycystic kidney disease
Yaerim Kim, Seungyeup Han
Korean J Intern Med. 2023;38(3):322-331. Published online April 25, 2023
As a genetic disease, there has been a long-standing effort to identify therapeutic options for autosomal dominant polycystic kidney disease (ADPKD). Following the development of tolvaptan, a vasopressin 2 receptor antagonist, the treatment strategy for ADPKD patients with rapid disease progression ..
|